Status:
UNKNOWN
Safety and Efficacy of Remimazolam in OPCAB Surgery
Lead Sponsor:
Ajou University School of Medicine
Conditions:
Coronary Artery Bypass Surgery
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
Remimazolam is a novel short-acting benzodiazepine drug that acts on the benzodiazepine binding site of gamma-aminobutryic acid (GABA) A receptor, is metabolized by esterase, and has a context-sensiti...
Eligibility Criteria
Inclusion
- Adult patients 19 years of age or older to receive OPCAB surgery
- Clinical diagnosis of coronary artery obstructive disease
Exclusion
- Ejection fraction \< 35% at preoperative ECHO test
- Mitral regurgitation \> grade 2 at preoperative ECHO test
- Currently using inotropics
- Currently receiving mechanical support
Key Trial Info
Start Date :
June 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2023
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT05396690
Start Date
June 15 2022
End Date
September 30 2023
Last Update
June 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ajou University Hospital
Suwon, Gyeonggido, South Korea